Option Millionaires

[nlightn]

$PFE,...New Pfizer bid unlikely says AstraZeneca CEO

"I consider it unlikely that Pfizer (NYSE:PFE) will return with a bid," reports Swedish business daily Dagens Industri quoting AstraZeneca (NYSE:AZN) CEO Pascal Soriot. "I can't say it will never happen, but the probability that Pfizer returns is much less."

Although British takeover rules now allow Pfizer to renew its pursuit of AstraZeneca, the recent U.S. clampdown on tax inversions makes an acquisition unlikely.

Pfizer also reached a major cancer drug deal with Merck KGaA last month, reducing its need for AstraZeneca's products.